Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FinlandBack to Finland

Clinical trials in Kokkola – page 2

26 clinical trials in Kokkola, Finland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Kokkola at a glance
26
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

26 trials in Kokkola

Open in trial search

Meningococcal infection

Not recruiting

Study of rMenB+OMV NZ meningococcal group B vaccine immune response and safety in previously vaccinated healthy participants aged 10 to 20 years

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide
  • Sponsor:GlaxoSmithKline Biologicals

Influenza immunisation

Not recruiting

Study on the Safety and Immune Response of a High-Dose Influenza Vaccine in Adults Aged 60 and Over, Comparing Trivalent Influenza Vaccine with a Drug Combination

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)
  • Sponsor:Abbott Biologicals B.V.

Respiratory syncytial virus infection

Not recruiting

Study on the Effectiveness and Safety of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers

Investigational
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:534
  • Sponsor:Sanofi Pasteur Inc.

Meningococcal immunisation

Not recruiting

Study on the Safety and Immune Response of a Booster Dose of MenACYW Conjugate Vaccine in Children and Adolescents Previously Vaccinated for Meningococcal Infection

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Tetanus toxoid
  • Sponsor:Sanofi Winthrop Industrie

Pneumococcal immunisation

Not recruiting

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Pneumococcal oligosaccharide serotype 18C conjugated to CRM197
  • Sponsor:Sanofi Pasteur Inc.

Study on the Safety and Effectiveness of Clesrovimab and Palivizumab for Preventing Severe RSV in Infants and Children at High Risk

Not recruiting
Registered drug
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Clesrovimab
  • Sponsor:Merck Sharp & Dohme LLC

Herpes zoster

Not recruiting

Study on Long-Term Effects and Safety of Herpes Zoster Vaccine with Recombinant Varicella Zoster Virus Glycoprotein E in Older Adults

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E
  • Sponsor:GlaxoSmithKline Biologicals

Pneumococcal infection

Not recruiting

Study on the Safety and Immune Response of PF-07831695 and a Drug Combination for Pneumococcal Infections in Healthy Toddlers Aged 12-15 Months

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:PF-07831695
  • Sponsor:Pfizer Inc.

Meningococcal infection

Not recruiting

Study on the Safety and Immune Response of MenACYW Conjugate Vaccine Compared to a Drug Combination in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid
  • Sponsor:Sanofi Pasteur

Influenza+1

Not recruiting

Study on the Effectiveness and Safety of OVX836 Vaccine for Preventing Influenza in Healthy Adults Aged 18-59

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Osivax

Respiratory syncytial virus infection

Not recruiting

Study on the Safety and Effectiveness of MK-1654 for Preventing Respiratory Syncytial Virus (RSV) in Healthy Pre-Term and Full-Term Infants

Registered drug
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Sponsor:Merck Sharp & Dohme LLC

Influenza

Not recruiting

Study of mRNA-1010 Influenza Vaccine Compared to Standard Flu Vaccine in Adults 50 Years and Older

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:CX-037231
  • Sponsor:Moderna Inc.

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Kokkola

What the registry says about research in the country

01 Respiratory Viral Infections

Extensive research focusing on respiratory syncytial virus (RSV) and influenza prevention through innovative vaccine development. Studies aim to protect both vulnerable populations and healthy adults.

  • RSV vaccines for older adults and infants
  • Influenza vaccine efficacy studies
  • Human Metapneumovirus prevention

Multiple clinical trials evaluating both preventive measures and therapeutic interventions for respiratory infections.

02 Bacterial Infections

Significant developments in preventing meningococcal and pneumococcal infections through advanced vaccine research, particularly focusing on pediatric populations.

  • Meningococcal conjugate vaccines
  • Pneumococcal vaccine studies
  • Long-term immunity evaluation

Research emphasizes vaccine safety and immunogenicity in different age groups.

03 Viral Disease Prevention

Comprehensive studies on Herpes Zoster and Cytomegalovirus prevention, exploring novel vaccine technologies including mRNA platforms.

  • CMV infection prevention
  • Herpes Zoster vaccine efficacy
  • Rhinovirus treatment studies

Focus on developing long-lasting immunity and reducing disease burden in susceptible populations.

04 Cardiovascular Research

Innovative research investigating emergency interventions for acute myocardial infarction, including self-administered treatments.

  • AMI emergency treatment
  • Preventive interventions
  • Patient self-management

Studies aim to improve outcomes in high-risk cardiac patients through rapid intervention strategies.

Back to FinlandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.